Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. (Q37911948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Deckert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A Engert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

W Brück

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A J M Ferreri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

J Finke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

G Illerhaus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

W Klapper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A Korfel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Maarouf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Montesinos-Rongen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

W Paulus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

U Schlegel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

O D Wiestler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

R Siebert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

5 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1797-1807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21818113%20AND%20SRC:MED&resulttype=core&format=json

Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

[Follicular and mantle cell lymphoma. Extranodal involvement of primarily nodal indolent B-cell lymphomas].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary central nervous system lymphoma in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Neuropathology of CNS disease in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Gene expression and angiotropism in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Pathway analysis of primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Array-based DNA methylation profiling of primary lymphomas of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Lymphoma stem cells: enough evidence to support their existence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Toxoplasma encephalitis of immunocompetent and nude mice: immunohistochemical characterisation of Toxoplasma antigen, infiltrates and major histocompatibility complex gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

A multicenter study of treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Glucocorticoid treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Temozolomide as salvage treatment in primary brain lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Delayed neurotoxicity in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Primary low-grade B-cell lymphoma of the dura: a mucosa associated lymphoid tissue-type lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Central nervous system vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Transcriptional Profiling of the Nuclear Factor-κB Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Epigenetic silencing of multiple genes in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Long-term survival in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Treatment for primary CNS lymphoma: the next step

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.169

7 January 2021